PREVENTION OF RENAL FIBROSIS BY SPIRONOLACTONE IN MICE WITH COMPLETE UNILATERAL URETERAL OBSTRUCTION
Abstract
Purpose:
Recent data suggest that aldosterone directly mediates cardiac fibrosis and hypertensive nephrosclerosis. We conducted experiments to determine whether administration of spironolactone, a mineralocorticoid receptor antagonist, reduced renal fibrosis in an experimental model of obstructive uropathy.
Materials and Methods:
Complete unilateral ureteral obstruction (UUO) was created surgically in 8 to 10-week-old male C57BL/6 mice by placing sutures around the right ureter. Spironolactone (50 mg/kg/daily) or 1% dimethyl sulfoxide vehicle was administered by subcutaneous injection for 1 to 2 weeks, and renal fibrosis was assessed by measuring trichrome staining and type I collagen deposition in the kidney.
Results:
UUO lasting 1 week was associated with minimal parenchymal damage and spironolactone had no demonstrable effect. In contrast, administration of the mineralocorticoid antagonist (8 mice) for a 2-week period significantly reduced renal fibrosis in the obstructed kidney, compared to mice given the dimethyl sulfoxide vehicle (9). The beneficial effect of spironolactone treatment was not associated with any changes in serum potassium or aldosterone concentration, or urinary concentrations of sodium or potassium.
Conclusions:
Administration of spironolactone reduced renal fibrosis in mice with UUO. These findings suggest that clinical trials are warranted to determine the efficacy of aldosterone antagonists in conjunction with angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers as renoprotective agents in patients with obstructive uropathy.
References
- 1 : Pathophysiology of progressive nephropathies. N Engl J Med1998; 339: 1448. Google Scholar
- 2 : Transforming growth factor-β and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis. Ann Rev Physiol1995; 57: 279. Google Scholar
- 3 : Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient level data. Ann Intern Med2001; 135: 73. Google Scholar
- 4 : Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int2000; 57: 1408. Google Scholar
- 5 : Chronic renal insufficiency in children and adolescents: the 1996 annual report of NAPRTCS. Pediatr Nephrol1998; 12: 328. Google Scholar
- 6 : The role of nitric oxide in obstructive uropathy. J Urol2000; 163: 1276. Link, Google Scholar
- 7 : Nitric oxide in obstructive uropathy: role of endothelial nitric oxide synthase. J Urol2002; 168: 1801. Link, Google Scholar
- 8 : Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive uropathy. Kidney Int1996; 49: 1110. Google Scholar
- 9 : Progression to end-stage renal disease in children with obstructive uropathy. J Pediatr1982; 100: 183. Google Scholar
- 10 : Molecular and cellular pathophysiology of obstructive nephropathy. Pediatr Nephrol1999; 13: 612. Google Scholar
- 11 : Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest1994; 93: 2431. Google Scholar
- 12 : Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int1994; 45: 916. Google Scholar
- 13 : Intragraft TGF-β1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int1996; 49: 1297. Google Scholar
- 14 : Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol2000; 32: 865. Google Scholar
- 15 : The renin-angiotensin system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol1996; 271: E883. Google Scholar
- 16 : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med1999; 341: 709. Google Scholar
- 17 : Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med2001; 345: 925. Google Scholar
- 18 : Unilateral ureteral obstruction impairs renal antioxidant enzyme activation during sodium depletion. Kidney Int1999; 55: 1327. Google Scholar
- 19 : Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int2002; 62: 1020. Google Scholar
- 20 : Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels. Am J Kidney Dis2002; 39: 486. Google Scholar
From the Departments of Pediatrics (HT), Pathology (EV) and Urology (ACW, LSP), Schneider Children's Hospital, and Animal Research Services (MM), North Shore-LIJ Health System, New Hyde Park, New York
